Drugs / Belvarafenib
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04835805 | May 2021 → Dec 2026 expected | melanoma | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07688356 | Jun 2026 → Jun 2028 expected | metastatic malignant neoplasm in the brain, primary brain neoplasm | Samsung Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07449754 | Feb 2026 → Sep 2029 expected | melanoma | Hanmi Pharmaceutical Company Limited | Recruiting | No outcome recorded |
| Phase 2 | NCT04589845 | Jan 2021 → Sep 2032 expected | cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Belvarafenib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07449754 ↗ |
| Action | Inhibit | “Belvarafenib is an oral pan-RAF inhibitor” NCT07688356 ↗ |
| Modality | Small molecule | — CHEMBL3977543 ↗ |
| Route | Oral | “400 mg, PO, BID” NCT04589845 ↗ |